Key result
Diabetes in AF linked to ~26% lower symptom perception and worse quality of life.
Why the study?
It remained unclear whether individual AF phenotype and related comorbidities differ between patients who have AF with and without diabetes.
Is diabetes mellitus associated with differences in atrial fibrillation phenotype (AF type, symptom perception, and quality of life) and cardiac and neurological comorbidities in patients with documented atrial fibrillation?
Cross-Sectional (n=2,411)
Yes
Is diabetes mellitus associated with differences in atrial fibrillation phenotype (AF type, symptom perception, and quality of life) and cardiac and neurological comorbidities in patients with documented atrial fibrillation?
Patients with atrial fibrillation and concomitant diabetes perceive AF symptoms less frequently despite having worse quality of life and higher rates of cardiac and neurological comorbidities, supporting heightened vigilance and potential screening for silent AF in diabetic patients.
Answers are grounded in this paper and cite their sources.
AF patients with diabetes may underreport symptoms despite worse quality of life; observational data leave open whether targeted screening improves detection or outcomes.
Background Diabetes is a major risk factor for atrial fibrillation (AF). However, it remains unclear whether individual AF phenotype and related comorbidities differ between patients who have AF with and without diabetes. This study investigated the association of diabetes with AF phenotype and cardiac and neurological comorbidities in patients with documented AF. Methods and Results Participants in the multicenter Swiss-AF (Swiss Atrial Fibrillation) study with data on diabetes and AF phenotype were eligible. Primary outcomes were parameters of AF phenotype, including AF type, AF symptoms, and quality of life (assessed by the European Quality of Life-5 Dimensions Questionnaire [EQ-5D]). Secondary outcomes were cardiac (ie, history of hypertension, myocardial infarction, and heart failure) and neurological (ie, history of stroke and cognitive impairment) comorbidities. The cross-sectional association of diabetes with these outcomes was assessed using logistic and linear regression, adjusted for age, sex, and cardiovascular risk factors. We included 2411 patients with AF (27.4% women; median age, 73.6 years). Diabetes was not associated with nonparoxysmal AF (odds ratio [OR], 1.01; 95% CI, 0.81-1.27). Patients with diabetes less often perceived AF symptoms (OR, 0.74; 95% CI, 0.59-0.92) but had worse quality of life (β=-4.54; 95% CI, -6.40 to -2.68) than those without diabetes. Patients with diabetes were more likely to have cardiac (hypertension [OR, 3.04; 95% CI, 2.19-4.22], myocardial infarction [OR, 1.55; 95% CI, 1.18-2.03], heart failure [OR, 1.99; 95% CI, 1.57-2.51]) and neurological (stroke [OR, 1.39, 95% CI, 1.03-1.87], cognitive impairment [OR, 1.75, 95% CI, 1.39-2.21]) comorbidities. Conclusions Patients who have AF with diabetes less often perceive AF symptoms but have worse quality of life and more cardiac and neurological comorbidities than those without diabetes. This raises the question of whether patients with diabetes should be systematically screened for silent AF. Registration URL: https://www.clinicaltrials.gov; Unique Identifier: NCT02105844.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted a cross-sectional in Documented atrial fibrillation (n=2,411). Diabetes mellitus vs. Patients with atrial fibrillation without diabetes mellitus was evaluated on Perception of any atrial fibrillation symptoms (OR 0.74, 95% CI 0.59-0.92, p=<0.001). Diabetes in patients with atrial fibrillation was associated with less perception of AF symptoms (OR 0.74, 95% CI 0.59-0.92) and worse quality of life (β=-4.54, 95% CI -6.40 to -2.68).
Synapse has enriched 10 related papers. Consider them for comparative context: